Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,078
archived clinical trials in
Major Depression Disorder (MDD)

A Study of Intermittent Doses of CERC-301 in MDD
A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment
Status: Enrolling
Updated:  9/25/2017
Summit Research Network (Oregon) Inc.
mi
from
Portland, OR
A Study of Intermittent Doses of CERC-301 in MDD
A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment
Status: Enrolling
Updated: 9/25/2017
Summit Research Network (Oregon) Inc.
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of Intermittent Doses of CERC-301 in MDD
A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment
Status: Enrolling
Updated:  9/25/2017
Lehigh Center for Clinical Research
mi
from
Allentown, PA
A Study of Intermittent Doses of CERC-301 in MDD
A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment
Status: Enrolling
Updated: 9/25/2017
Lehigh Center for Clinical Research
mi
from
Allentown, PA
Click here to add this to my saved trials
A Study of Intermittent Doses of CERC-301 in MDD
A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment
Status: Enrolling
Updated:  9/25/2017
Northwest Clinical Research Center
mi
from
Bellevue, WA
A Study of Intermittent Doses of CERC-301 in MDD
A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment
Status: Enrolling
Updated: 9/25/2017
Northwest Clinical Research Center
mi
from
Bellevue, WA
Click here to add this to my saved trials
A Study of Intermittent Doses of CERC-301 in MDD
A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment
Status: Enrolling
Updated:  9/25/2017
Chicago Research Center, Inc
mi
from
Chicago, IL
A Study of Intermittent Doses of CERC-301 in MDD
A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment
Status: Enrolling
Updated: 9/25/2017
Chicago Research Center, Inc
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Intermittent Doses of CERC-301 in MDD
A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment
Status: Enrolling
Updated:  9/25/2017
Alexian Brothers Center for Psychiatric Research
mi
from
Hoffman Estates, IL
A Study of Intermittent Doses of CERC-301 in MDD
A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment
Status: Enrolling
Updated: 9/25/2017
Alexian Brothers Center for Psychiatric Research
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
A Study of Intermittent Doses of CERC-301 in MDD
A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment
Status: Enrolling
Updated:  9/25/2017
Richmond Behavioral Associates
mi
from
Staten Island, NY
A Study of Intermittent Doses of CERC-301 in MDD
A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment
Status: Enrolling
Updated: 9/25/2017
Richmond Behavioral Associates
mi
from
Staten Island, NY
Click here to add this to my saved trials
A Study of Intermittent Doses of CERC-301 in MDD
A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment
Status: Enrolling
Updated:  9/25/2017
Research Strategies of Memphis, LLC
mi
from
Memphis, TN
A Study of Intermittent Doses of CERC-301 in MDD
A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment
Status: Enrolling
Updated: 9/25/2017
Research Strategies of Memphis, LLC
mi
from
Memphis, TN
Click here to add this to my saved trials
Insulin Resistance in Patients With Major Depression
Insulin Resistance in Patients With Major Depression
Status: Enrolling
Updated:  10/3/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Insulin Resistance in Patients With Major Depression
Insulin Resistance in Patients With Major Depression
Status: Enrolling
Updated: 10/3/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE 4) in Depressed Patients
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE 4) in Depressed Patients
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
MRI Study of Brain Activity and Risk for Depression in Adolescents
Neural Circuitry and Risk for Depression in Adolescents: A Study Using Functional Magnetic Resonance Imaging
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
MRI Study of Brain Activity and Risk for Depression in Adolescents
Neural Circuitry and Risk for Depression in Adolescents: A Study Using Functional Magnetic Resonance Imaging
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Clinical Study to Test a New Drug to Treat Major Depression
A Six Week Randomized, Double-blind, Multi-center, Placebo-controlled, Exploratory, Adaptive Design Study to Explore the Antidepressant Properties of the p38 MAP Kinase Inhibitor GW856553 Compared to Placebo in Adult Subjects With Major Depressive Disorder
Status: Enrolling
Updated:  10/11/2017
GSK Investigational Site
mi
from
Hoffman Estates, IL
Clinical Study to Test a New Drug to Treat Major Depression
A Six Week Randomized, Double-blind, Multi-center, Placebo-controlled, Exploratory, Adaptive Design Study to Explore the Antidepressant Properties of the p38 MAP Kinase Inhibitor GW856553 Compared to Placebo in Adult Subjects With Major Depressive Disorder
Status: Enrolling
Updated: 10/11/2017
GSK Investigational Site
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
Clinical Study to Test a New Drug to Treat Major Depression
A Six Week Randomized, Double-blind, Multi-center, Placebo-controlled, Exploratory, Adaptive Design Study to Explore the Antidepressant Properties of the p38 MAP Kinase Inhibitor GW856553 Compared to Placebo in Adult Subjects With Major Depressive Disorder
Status: Enrolling
Updated:  10/11/2017
GSK Investigational Site
mi
from
Park Ridge, IL
Clinical Study to Test a New Drug to Treat Major Depression
A Six Week Randomized, Double-blind, Multi-center, Placebo-controlled, Exploratory, Adaptive Design Study to Explore the Antidepressant Properties of the p38 MAP Kinase Inhibitor GW856553 Compared to Placebo in Adult Subjects With Major Depressive Disorder
Status: Enrolling
Updated: 10/11/2017
GSK Investigational Site
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Clinical Study to Test a New Drug to Treat Major Depression
A Six Week Randomized, Double-blind, Multi-center, Placebo-controlled, Exploratory, Adaptive Design Study to Explore the Antidepressant Properties of the p38 MAP Kinase Inhibitor GW856553 Compared to Placebo in Adult Subjects With Major Depressive Disorder
Status: Enrolling
Updated:  10/11/2017
GSK Investigational Site
mi
from
New York, NY
Clinical Study to Test a New Drug to Treat Major Depression
A Six Week Randomized, Double-blind, Multi-center, Placebo-controlled, Exploratory, Adaptive Design Study to Explore the Antidepressant Properties of the p38 MAP Kinase Inhibitor GW856553 Compared to Placebo in Adult Subjects With Major Depressive Disorder
Status: Enrolling
Updated: 10/11/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Clinical Study to Test a New Drug to Treat Major Depression
A Six Week Randomized, Double-blind, Multi-center, Placebo-controlled, Exploratory, Adaptive Design Study to Explore the Antidepressant Properties of the p38 MAP Kinase Inhibitor GW856553 Compared to Placebo in Adult Subjects With Major Depressive Disorder
Status: Enrolling
Updated:  10/11/2017
GSK Investigational Site
mi
from
Columbus, OH
Clinical Study to Test a New Drug to Treat Major Depression
A Six Week Randomized, Double-blind, Multi-center, Placebo-controlled, Exploratory, Adaptive Design Study to Explore the Antidepressant Properties of the p38 MAP Kinase Inhibitor GW856553 Compared to Placebo in Adult Subjects With Major Depressive Disorder
Status: Enrolling
Updated: 10/11/2017
GSK Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Clinical Study to Test a New Drug to Treat Major Depression
A Six Week Randomized, Double-blind, Multi-center, Placebo-controlled, Exploratory, Adaptive Design Study to Explore the Antidepressant Properties of the p38 MAP Kinase Inhibitor GW856553 Compared to Placebo in Adult Subjects With Major Depressive Disorder
Status: Enrolling
Updated:  10/11/2017
GSK Investigational Site
mi
from
Pazardzhik,
Clinical Study to Test a New Drug to Treat Major Depression
A Six Week Randomized, Double-blind, Multi-center, Placebo-controlled, Exploratory, Adaptive Design Study to Explore the Antidepressant Properties of the p38 MAP Kinase Inhibitor GW856553 Compared to Placebo in Adult Subjects With Major Depressive Disorder
Status: Enrolling
Updated: 10/11/2017
GSK Investigational Site
mi
from
Pazardzhik,
Click here to add this to my saved trials
Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study
SSRI Versus Bupropion in High-Risk Major Depressive Disorder
Status: Enrolling
Updated:  10/19/2017
Columbia University/New York State Psychiatric Institute
mi
from
New York, NY
Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study
SSRI Versus Bupropion in High-Risk Major Depressive Disorder
Status: Enrolling
Updated: 10/19/2017
Columbia University/New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
Effects of Treatment on Decision-making in Major Depression
Effects of Treatment on Decision-making in Major Depression
Status: Enrolling
Updated:  10/19/2017
Emory Mood and Anxiety Disorders Program
mi
from
Atlanta, GA
Effects of Treatment on Decision-making in Major Depression
Effects of Treatment on Decision-making in Major Depression
Status: Enrolling
Updated: 10/19/2017
Emory Mood and Anxiety Disorders Program
mi
from
Atlanta, GA
Click here to add this to my saved trials
Transcranial Laser Therapy for Major Depressive Disorder
Evaluation of LED Therapeutic Effect in Depression (ELATED): a Placebo-Controlled, Parallel Study of Efficacy, Tolerability and Acceptability of a Novel Approach in the Community
Status: Enrolling
Updated:  10/24/2017
Massachusetts General Hospital- Depression Clinical and Research Program
mi
from
Boston, MA
Transcranial Laser Therapy for Major Depressive Disorder
Evaluation of LED Therapeutic Effect in Depression (ELATED): a Placebo-Controlled, Parallel Study of Efficacy, Tolerability and Acceptability of a Novel Approach in the Community
Status: Enrolling
Updated: 10/24/2017
Massachusetts General Hospital- Depression Clinical and Research Program
mi
from
Boston, MA
Click here to add this to my saved trials
Transcranial Laser Therapy for Major Depressive Disorder
Evaluation of LED Therapeutic Effect in Depression (ELATED): a Placebo-Controlled, Parallel Study of Efficacy, Tolerability and Acceptability of a Novel Approach in the Community
Status: Enrolling
Updated:  10/24/2017
Chelsea Counseling Center- North Suffolk Mental Health Association
mi
from
Chelsea, MA
Transcranial Laser Therapy for Major Depressive Disorder
Evaluation of LED Therapeutic Effect in Depression (ELATED): a Placebo-Controlled, Parallel Study of Efficacy, Tolerability and Acceptability of a Novel Approach in the Community
Status: Enrolling
Updated: 10/24/2017
Chelsea Counseling Center- North Suffolk Mental Health Association
mi
from
Chelsea, MA
Click here to add this to my saved trials
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated:  10/31/2017
CNS Trials
mi
from
Garden Grove, CA
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated: 10/31/2017
CNS Trials
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated:  10/31/2017
Synergy Escondido
mi
from
Lemon Grove, CA
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated: 10/31/2017
Synergy Escondido
mi
from
Lemon Grove, CA
Click here to add this to my saved trials
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated:  10/31/2017
Pacific Trials Partners
mi
from
Oakland, CA
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated: 10/31/2017
Pacific Trials Partners
mi
from
Oakland, CA
Click here to add this to my saved trials
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated:  10/31/2017
Sarkis Clinical Trials
mi
from
Gainesville, FL
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated: 10/31/2017
Sarkis Clinical Trials
mi
from
Gainesville, FL
Click here to add this to my saved trials
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated:  10/31/2017
CNS Healthcare, Inc
mi
from
Jacksonville, FL
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated: 10/31/2017
CNS Healthcare, Inc
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated:  10/31/2017
Segal Institute
mi
from
Lauderhill, FL
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated: 10/31/2017
Segal Institute
mi
from
Lauderhill, FL
Click here to add this to my saved trials
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated:  10/31/2017
Institute for Advanced Medical Research
mi
from
Alpharetta, GA
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated: 10/31/2017
Institute for Advanced Medical Research
mi
from
Alpharetta, GA
Click here to add this to my saved trials
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated:  10/31/2017
Radiant Research, Inc.
mi
from
Atlanta, GA
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated: 10/31/2017
Radiant Research, Inc.
mi
from
Atlanta, GA
Click here to add this to my saved trials
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated:  10/31/2017
Neurobehavioral Clinical Research
mi
from
Canton, OH
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated: 10/31/2017
Neurobehavioral Clinical Research
mi
from
Canton, OH
Click here to add this to my saved trials
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated:  10/31/2017
Midwest Clinical
mi
from
Dayton, OH
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated: 10/31/2017
Midwest Clinical
mi
from
Dayton, OH
Click here to add this to my saved trials
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated:  10/31/2017
Future Search Trials
mi
from
Dallas, TX
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated: 10/31/2017
Future Search Trials
mi
from
Dallas, TX
Click here to add this to my saved trials
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated:  10/31/2017
Northwest Clinical Research Center
mi
from
Bellevue, WA
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Status: Enrolling
Updated: 10/31/2017
Northwest Clinical Research Center
mi
from
Bellevue, WA
Click here to add this to my saved trials
Slow-wave Sleep Deprivation in Depression
Slow-wave Sleep Deprivation as a Possible Treatment for Major Depressive Disorder
Status: Enrolling
Updated:  11/6/2017
Wisconsin Center for Sleep Medicine and Research
mi
from
Madison, WI
Slow-wave Sleep Deprivation in Depression
Slow-wave Sleep Deprivation as a Possible Treatment for Major Depressive Disorder
Status: Enrolling
Updated: 11/6/2017
Wisconsin Center for Sleep Medicine and Research
mi
from
Madison, WI
Click here to add this to my saved trials
Study Comparing Magnetic Seizure Therapy (MST) to Electroconvulsive Therapy (ECT) for Depression in Older Adults
Improving Outcomes in Geriatric Depression: Magnetic Seizure Therapy
Status: Enrolling
Updated:  11/13/2017
New York State Psychiatric Institute
mi
from
New York, NY
Study Comparing Magnetic Seizure Therapy (MST) to Electroconvulsive Therapy (ECT) for Depression in Older Adults
Improving Outcomes in Geriatric Depression: Magnetic Seizure Therapy
Status: Enrolling
Updated: 11/13/2017
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated:  11/21/2017
Woodland International Research Group
mi
from
Little Rock, AK
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated: 11/21/2017
Woodland International Research Group
mi
from
Little Rock, AK
Click here to add this to my saved trials
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated:  11/21/2017
CITrials, Inc.
mi
from
Bellflower, CA
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated: 11/21/2017
CITrials, Inc.
mi
from
Bellflower, CA
Click here to add this to my saved trials
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated:  11/21/2017
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated: 11/21/2017
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Click here to add this to my saved trials
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated:  11/21/2017
Behavioral Research Specialists, LLC
mi
from
Glendale, CA
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated: 11/21/2017
Behavioral Research Specialists, LLC
mi
from
Glendale, CA
Click here to add this to my saved trials
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated:  11/21/2017
Excell Research, Inc.
mi
from
Oceanside, CA
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated: 11/21/2017
Excell Research, Inc.
mi
from
Oceanside, CA
Click here to add this to my saved trials
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated:  11/21/2017
NRC Research Institute
mi
from
Orange, CA
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated: 11/21/2017
NRC Research Institute
mi
from
Orange, CA
Click here to add this to my saved trials
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated:  11/21/2017
Artemis Institute for Clinical Research
mi
from
San Diego, CA
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated: 11/21/2017
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated:  11/21/2017
Schuster Medical Research Institute
mi
from
Sherman Oaks, CA
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated: 11/21/2017
Schuster Medical Research Institute
mi
from
Sherman Oaks, CA
Click here to add this to my saved trials
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated:  11/21/2017
Sarkis Clinical Trials
mi
from
Gainesville, FL
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated: 11/21/2017
Sarkis Clinical Trials
mi
from
Gainesville, FL
Click here to add this to my saved trials
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated:  11/21/2017
Compass Research, LLC: North Clinic
mi
from
Leesburg, FL
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated: 11/21/2017
Compass Research, LLC: North Clinic
mi
from
Leesburg, FL
Click here to add this to my saved trials
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated:  11/21/2017
Research Centers of America, LLC
mi
from
Oakland Park, FL
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated: 11/21/2017
Research Centers of America, LLC
mi
from
Oakland Park, FL
Click here to add this to my saved trials
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated:  11/21/2017
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated: 11/21/2017
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Click here to add this to my saved trials
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated:  11/21/2017
Compass Research LLC
mi
from
Orlando, FL
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated: 11/21/2017
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated:  11/21/2017
Stedman Clinical Trials
mi
from
Tampa, FL
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated: 11/21/2017
Stedman Clinical Trials
mi
from
Tampa, FL
Click here to add this to my saved trials
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated:  11/21/2017
Institute for Advanced Medical Research
mi
from
Alpharetta, GA
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated: 11/21/2017
Institute for Advanced Medical Research
mi
from
Alpharetta, GA
Click here to add this to my saved trials
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated:  11/21/2017
Atlanta Center for Medical Research
mi
from
Atlanta, GA
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated: 11/21/2017
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated:  11/21/2017
iResearch Atlanta LLC
mi
from
Decatur, GA
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females
Status: Enrolling
Updated: 11/21/2017
iResearch Atlanta LLC
mi
from
Decatur, GA
Click here to add this to my saved trials